Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

Journal of the National Cancer Institute

Volumn 94, Issue 2, 2002, Pages 116-128

  Look, Maxime P ^a,t   Van Putten, Wim L J ^a   Duffy, Michael J ^b   Harbeck, Nadia ^c   Christensen, Ib Jarle ^d   Thomssen, Christoph ^e   Kates, Ronald ^c   Spyratos, Frédérique ^f   Fernö, Mårten ^g   Eppenberger Castori, Serenella ^h   Sweep, C G J Fred ⁱ   Ulm, Kurt ^c   Peyrat, Jean Philippe ^j   Martin, Pierre Marie ^k   Magdelenat, Henri ^l   Brünner, Nils ^d   Duggan, Catherine ^b   Lisboa, Björn W ^e   Bendahl, Pär Ola ^g   Quillien, Véronique ^m   Daver, Alain ⁿ   Ricolleau, Gabriel ^o   Meijer Van Gelder, Marion E ^a   Manders, Peggy ⁱ   Fiets, W Edward ^p   Blankenstein, Marinus A ^p   Broët, Philippe ^l   Romain, Sylvie ^k   Daxenbichler, Günter ^q   Windbichler, Gudrun ^q   Cufer, Tanja ^r   Borstnar, Simona ^r   Kueng, Willy ^h   Beex, Louk V A M ⁱ   Klijn, Jan G M ^a   O'Higgins, Niall ^s   Eppenberger, Urs ^h   Jänicke, Fritz ^e   Schmitt, Manfred ^c   Foekens, John A ^a   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Laboratoire de Biologie Tissulaire   (France)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j CENTRE OSCAR LAMBRET   (France)

^k Laboratoire de Transfert d'Oncologie Biologique (AP HM)   (France)

^l INSTITUT CURIE   (France)

^m CENTRE EUGÈNE MARQUIS   (France)

ⁿ CENTRE PAUL PAPIN   (France)

^o CENTRE RENÉ GAUDUCHEAU   (France)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^r INSTITUTE OF ONCOLOGY   (Slovenia)

^s UNIVERSITY COLLEGE DUBLIN   (Ireland)

^t JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROID RECEPTOR; TISSUE EXTRACT; UROKINASE;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INDIVIDUALIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RECURRENCE RISK; REGRESSION ANALYSIS; TREATMENT PLANNING;

EID: 0037116616     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.2.116     Document Type: Article

References (40)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
4. Modulators of the urokinase-type plasminogen activation system for cancer
5. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
6. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report
7. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer
8. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
9. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release
10. 3 binding to vitronectin
11. Proteases as prognostic markers in cancer
12. Clinical relevance of the urokinase plasminogen activator system in breast cancer
13. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
14. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
15. Dissemination risk index based on plasminogen activator system components in primary breast cancer
16. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
17. Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease
18. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
19. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers
20. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicentre study
21. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
22. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer
23. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
24. Plasminogen activator inhibitor type I in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
25. The complex between urokinase and its type-1 inhibitor in primary breast cancer: Relation to survival
26. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
27. Breast cancer
28. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols
29. Protein measurement with folin phenol reagent
30. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
31. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop
32. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: Comparison of two immunoassay methods
33. Meta-analysis in clinical trials
34. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
35. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients
36. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
37. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful
38. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
39. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors